1. Lee TKW, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma-from origin to clinical implications. Nat Rev Gastroenterol Hepatol 2022; 19: 26-44.
2.
Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin Mol Hepatol 2023; 29: 605-22.
3.
Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet 2022; 400: 1345-62.
4.
Xu FQ, Dong MM, Wang ZF, et al. Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma. Front Immunol 2023; 14. https://doi.org/10.3389/fimmu.2023.1083069
5.
Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sinica B 2022; 12: 558-80.
6.
Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology 2023; 77: 1773-96.
7.
Valente LC, Bacil GP, Riechelmann-Casarin L, et al. Exploring in vitro modeling in hepatocarcinogenesis research: morphological and molecular features and similarities to the corresponding human disease. Life Sci 2024; 351: 122781.
8.
Gu A, Li J, Li MY, et al. Patient-derived xenograft model in cancer: establishment and applications. Medcomm 2025; 6: e70059.
9.
Airola C, Pallozzi M, Cesari E, et al. Hepatocellular-carcinoma-derived organoids: innovation in cancer research. Cells 2024; 13: 1726.
10.
Xu H, Jiao D, Liu A, et al. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol 2022; 15: 58.
11.
Li L, Selaru FM. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Adv Cancer Res 2022; 156: 319-41.
12.
Hogenson TL, Xie H, Phillips WJ, et al. Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers. JCI Insight 2022; 7(22). DOI: 10.1172/jci.insight.158060.
13.
He T, Zou J, Sun K, Yang J. Global research status and frontiers on autophagy in hepatocellular carcinoma: a comprehensive bibliometric and visualized analysis. Int J Surg 2024; 110: 2788-802.
14.
Xiao N, Huang X, Zang W, et al. Health-related quality of life in patients with inborn errors of immunity: a bibliometric analysis. Front Immunol 2024; 15: 1371124.
15.
Tian S, Chen M. Global research progress of gut microbiota and epigenetics: bibliometrics and visualized analysis. Front Immunol 2024; 15: 1412640.
16.
Close DA, Johnston PA. Miniaturization and characterization of patient derived hepatocellular carcinoma tumor organoid cultures for cancer drug discovery applications. Slas Discov 2025; 30: 100201.
17.
Khedr MA, Mohamed Z, El-Derby AM, et al. Development of hepatocellular carcinoma organoid model recapitulating HIF-1A metabolic signature. Clin Exp Med 2024; 25: 9.
18.
Song J, Lu M, He Z, Zhang W. Models of fibrolamellar carcinomas, tools for evaluation of a new era of treatments. Front Immunol 2024; 15: 1459942.
19.
El-Derby AM, Khedr MA, Ghoneim NI, et al. Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma. J Transl Med 2024; 22: 487.
20.
Lau HCH, Zhang X, Ji F, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. Ebiomedicine 2024; 100: 104952.
21.
Yoon Y, Gong SC, Kim MY, et al. Generation of fibrotic liver organoids using hepatocytes, primary liver sinusoidal endothelial cells, hepatic stellate cells, and macrophages. Cells 2023; 12: 2514.
22.
Narayan NJC, Requena D, Lalazar G, et al. Human liver organoids for disease modeling of fibrolamellar carcinoma. Stem Cell Rep 2022; 17: 1874-88.
23.
Tang C, Tang C, Zhu X, et al. Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma. Br J Pharmacol 2025; 182: 1394-409.
24.
Wang J, Yu H, Dong W, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells’ properties and lenvatinib resistance through WNT/b-Catenin and hippo signaling pathways. Gastroenterology 2023; 164: 990-1005.
25.
Ma S, Xie F, Wen X, et al. GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma. Pharmacol Res 2024; 210: 107490.
26.
Sun L, Wan AH, Yan S, et al. A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance. Acta Pharm Sin B 2024; 14: 223-40.
27.
Zou Z, Lin Z, Wu C, et al. Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients. Adv Sci 2023; 10: e2302640.
28.
Xu F, Tong M, Tong CSW, et al. A combinatorial CRISPR-Cas9 screen identifies ifenprodil as an adjunct to sorafenib for liver cancer treatment. Cancer Res 2021; 81: 6219-32.
29.
Mansouri M, Imes WDD, Roberts OSS, et al. Fabrication of oxygen-carrying microparticles functionalized with liver ECM-proteins to improve phenotypic three-dimensional in vitro liver assembly, function, and responses. Biotechnol Bioeng 2023; 120: 3025-38.
30.
Yang H, Cheng J, Zhuang H, et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell 2024; 42: 535-1.e8.
31.
Rialdi A, Duffy M, Scopton AP, et al. WNTinib is a multi-kinase inhibitor with specificity against b-catenin mutant hepatocellular carcinoma. Nat Cancer 2023; 4: 1157-75.
32.
Lam YK, Yu J, Huang H, et al. TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk. Hepatology 2023; 78: 727-40.
33.
Ma X, Wang Q, Li G, et al. Cancer organoids: a platform in basic and translational research. Genes Dis 2024; 11: 614-32.
34.
Xu L, Liu Q, Liu H, et al. Disrupting CCDC137-mediated LZTS2 and b-TrCP interaction in the nucleus inhibits hepatocellular carcinoma development via b-catenin and AKT. Cell Death Differ 2025; 32: 134-48.
